Payment overview · 2025
General Payments
$113.32
7 reported records · 5 companies
Healthcare provider profile · identity verified
Arif Aziz Somjee, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ASHLAND, MS · NPI 1730129404
Verified facts
What the public records show
CMS Open Payments records show Arif Aziz Somjee, MD received $113.32 in general payments during 2025 across 7 reported records.
Amgen Inc. accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.52 | 26.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.79 | 24.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.94 | 17.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.46 | 16.3% | 1 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $17.61 | 15.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $113.32 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.52 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.79 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 176 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
53 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
176 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 614 | 168 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 413 | 108 |
| Fluticasone Propionate | Fluticasone Propionate | 390 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 313 | 89 |
| Gabapentin | Gabapentin | 300 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 283 | 92 |
| Potassium Chloride | Potassium Chloride | 281 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 268 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 255 | 66 |
| Losartan Potassium | Losartan Potassium | 252 | 71 |
| Jardiance | Empagliflozin | 239 | 66 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 235 | 61 |
| Furosemide | Furosemide | 227 | 58 |
| Omeprazole | Omeprazole | 215 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 202 | 50 |
| Metformin Hcl Er | Metformin Hcl | 183 | 54 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 176 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 160 | 43 |
| Lisinopril | Lisinopril | 150 | 44 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 148 | 37 |
| Ozempic | Semaglutide | 136 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 33 |
| Allopurinol | Allopurinol | 131 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 125 | 35 |
| Meloxicam | Meloxicam | 124 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 123 | 53 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 122 | 32 |
| Metformin Hcl | Metformin Hcl | 119 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 30 |
| Naproxen | Naproxen | 113 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 112 | 59 |
| Eliquis | Apixaban | 111 | 30 |
| Carvedilol | Carvedilol | 109 | 31 |
| Novolog Flexpen | Insulin Aspart | 105 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 100 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 23 |
| Famotidine | Famotidine | 99 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 29 |
| Trazodone Hcl | Trazodone Hcl | 96 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 28 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 90 | 26 |
| Montelukast Sodium | Montelukast Sodium | 82 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 25 |
| Clonidine Hcl | Clonidine Hcl | 76 | 24 |
| Pregabalin | Pregabalin | 74 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 73 | 24 |
| Xarelto | Rivaroxaban | 72 | 14 |
| Spironolactone | Spironolactone | 68 | 13 |
| Vascepa | Icosapent Ethyl | 67 | 14 |
| Buspirone Hcl | Buspirone Hcl | 64 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 63 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 17 |
| Mounjaro | Tirzepatide | 62 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 61 | 17 |
| Mupirocin | Mupirocin | 60 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 54 | 13 |
| Ibuprofen | Ibuprofen | 54 | 13 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 54 | 18 |
| Januvia | Sitagliptin Phosphate | 53 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 53 | 35 |
| Farxiga | Dapagliflozin Propanediol | 52 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 16 |
| Pen Needles | Pen Needle, Diabetic | 49 | 15 |
| Sertraline Hcl | Sertraline Hcl | 49 | 14 |
| Simvastatin | Simvastatin | 49 | 16 |
| Finasteride | Finasteride | 47 | suppressed |
| Linzess | Linaclotide | 47 | 16 |
| Trulicity | Dulaglutide | 47 | 12 |
| Alprazolam | Alprazolam | 45 | suppressed |
| Atenolol | Atenolol | 45 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 13 |
| Cephalexin | Cephalexin | 43 | 33 |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 39 | suppressed |
| Prednisone | Prednisone | 38 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Levemir Flexpen | Insulin Detemir | 37 | 15 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 23 |
| Ezetimibe | Ezetimibe | 34 | 11 |
| Methylprednisolone | Methylprednisolone | 34 | 31 |
| Brilinta | Ticagrelor | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 33 | 11 |
| Baclofen | Baclofen | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 24 |
| Nitroglycerin | Nitroglycerin | 28 | 11 |
| Donepezil Hcl | Donepezil Hcl | 27 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Azithromycin | Azithromycin | 26 | 25 |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Glimepiride | Glimepiride | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Cimetidine | Cimetidine | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $113.32 · 7 records | Amgen Inc. | AIRSUPRA, EGRIFTA, FREESTYLE LIBRE, REPATHA, TRELEGY ELLIPTA, TROGARZO | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error